Company Email Format Management

VBL Therapeutics (Nasdaq:VBLT)

Biotechnology Research Modi'in Makkabbim Re'ut, Il 14 employees VBLT

Employees: 14
Contacts: 2
Emails: 2

www.vblrx.com LinkedIn Crunchbase

VBL Therapeutics (Nasdaq:VBLT) Overview

Headquarters: Modi'in Makkabbim Re'ut, Il
Phone Number: Available in AeroLeads
Website: www.vblrx.com
Industry: Biotechnology Research
Employees: 14
Founded: 2000
Stock Symbol: VBLT
Funding: 16.9M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Biotech / Pharma Innovation Immune-Inflammatory

About VBL Therapeutics (Nasdaq:VBLT)

VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.

VBL Therapeutics (Nasdaq:VBLT) Contact Details

People in AeroLeads: 4
With contact data: 2
Email contacts: 2; 50.0% coverage

VBL Therapeutics (Nasdaq:VBLT) Org Chart

Sample employees and titles

Name	Title	Location	Contact
Shifra Fain-Shmueli	Director of Clinical Operations at Vascular Biogenics Ltd. (Also Known as Vbl Therapeutics)	Israel	Email
Niva Yacov	Business Development Associate and Head of Pre-clinical Studies at Vbl Therapeutics	Israel	View
Hagit Ben Shabat		Israel	View
Avi Cohen	Biological Researcher Teva	Israel	Email